Berger Financial Group, Inc Gilead Sciences, Inc. Transaction History

Berger Financial Group, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	SELL	$77.31 - $88.08 $5.39 Million - $6.14 Million	-69,721 Reduced 96.53%	2,508 $208,000
Q4 2022 Jan 30, 2023	BUY	$62.32 - $89.47 $53,158 - $76,317	853 Added 1.2%	72,229 $6.2 Million
Q3 2022 Oct 27, 2022	BUY	$59.54 - $68.01 $132,476 - $151,322	2,225 Added 3.22%	71,376 $4.4 Million
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $87,214 - $98,230	1,511 Added 2.23%	69,151 $4.27 Million
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $3.92 Million - $4.91 Million	67,640 New	67,640 $4.02 Million
Q1 2021 May 12, 2021	SELL	$60.0 - $68.46 $3.48 Million - $3.97 Million	-57,942 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$56.65 - $64.55 $3.28 Million - $3.74 Million	57,942 New	57,942 $3.38 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Berger Financial Group, Inc, based on Form 13F filings with the SEC.

Stay updated on Berger Financial Group, Inc with notifications on news.